Siponimod under consideration for treatment of secondary progressive MS
4 September 2019
Secondary progressive MS, a form of MS that can follow on from relapsing remitting MS, currently has no
Secondary progressive MS, a form of MS that can follow on from relapsing remitting MS, currently has no
The PBAC has recommended the PBS criteria for two existing MS medications, Gilenya and Tysabri, be broadened which would allow reimbursement for young people with MS.
On the SBS Insight program the focus of the discussion was how people live with and manage their MS. The program touched on a number of topics such as the different treatments available for MS, including AHSCT and how different women with MS had approached pregnancy and breastfeeding.
Australian researchers used cognitive eye movement tasks and MRI to look at changes in cognition and brain activity in people with CIS
Up to 65% of people with MS report difficulties with thinking and memory, but many cognitive tests cause
Previous research suggests that opicinumab treatment might enhance remyelination. Results from a phase 2 clinical trial testing the
There is growing evidence that lifestyle factors may impact the onset or progression of MS, and that adolescence
Professor David Booth is carrying out a project looking at how the combination of someone’s genetics and vitamin D may influence the risk of getting MS.
An Australian research team supported by MS Research Australia has developed a non-invasive method to boost the production of myelin in the brain.